GenSight Biologics has successfully transferred the upstream phase of its manufacturing process for LUMEVOQ® to Catalent, marking a significant milestone in their partnership. This collaboration aims to improve production yield and enhance analytical methods before clinical use and regulatory submissions.
Company Information
Company
GenSight Biologics
Location
Paris, Ile-de-France, France
About
GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
ParisBiotechnologyHealth CareTherapeuticsBiopharma